The annual Movember campaign has put prostate cancer firmly in the limelight – and with good reason: a leading UK based cancer charity predicts that it will be the most diagnosed cancer in the UK by 2030. Here is what you need to know about the most common male cancer.
The annual Movember campaign has put prostate cancer firmly in the limelight – and with good reason: a leading UK based cancer charity predicts that it will be the most diagnosed cancer in the UK by 2030.
A number of public figures have battled the disease including actor Sir Ian McKellen, entertainer Bob Monkhouse and the current US Secretary of State, John Kerry.
Recent studies have suggested that blood tests, such as Medichecks’ prostate cancer test may play a big part in the identification of the condition in future.
Here is what you need to know about the most common male cancer.
Cancer Research UK announced in 2011 that in there were 41,736 new cases of prostate cancer diagnosed in the UK (http://bit.ly/1iQv0zw). A more recent study by the American Cancer Society found that so far this year (2015) there have been over 220,800 new cases of prostate cancer diagnosed in the US alone (http://bit.ly/Jj7BoB), making it as the most common male cancer in the United States.
Survival rates, if caught early are good: research has found that in 2010-2011 84% of patients successfully battled the disease; but with rates of diagnosis expanding, blood tests will play an increasingly important role in the diagnosis and treatment of prostate cancer. Indeed the NHS have said that one of the best ways to stay ahead of prostate cancer is through blood tests (http://bit.ly/1PeprJM).
The Medichecks Prostate Check analyses the levels of PSA (prostate specific antigen) in the blood stream. A raised level may be cause for further investigation and might lead to an early discovery of prostate cancer, which could significantly increase rates of survival. Many doctors fear that prostate cancer is over-diagnosed and over-treated. In some cases a raised PSA level might simply be monitored in a “watchful waiting” strategy. In either case, knowing your starting point for PSA is an important part of disease detection and progression.
All Medichecks’ tests are accurate and affordable, with results being delivered discreetly and confidentially from approved and accredited laboratories.
Further information about the Medichecks prostate cancer test can be found here: https://www.medichecks.com/cancer-markers